tbuckley/cabot-search huggingface dataset:
Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial
Authors: Jerry Bagel, Linda Stein Gold, James Del Rosso, Sandy Johnson, Paul Yamauchi, Philip M. Brown, Neal Bhatia, Angela Yen Moore, Anna M. Tallman
Journal: Journal of the American Academy of Dermatology (2023)

Tapinarof cream 1% once daily demonstrated significant efficacy versus vehicle and was well tolerated in two 12-week, phase 3 pivotal trials in adults with mild-to-severe plaque psoriasis.To assess long-term, health-related quality of life and patient satisfaction with tapinarof.Patients completing the 12-week trials were eligible for 40 weeks of open-label tapinarof based on Physician Global Assessment score in PSOARING 3, with a 4-week follow-up. Dermatology Life Quality Index was assessed at every visit; Patient Satisfaction Questionnaire responses were assessed at week 40 or early termination.Seven hundred sixty-three (91.6%) eligible patients enrolled; 78.5% completed the Patient Satisfaction Questionnaire. DLQI scores improved and were maintained. By week 40, 68.0% of patients had a DLQI of 0 or 1, indicating no impact of psoriasis on health-related quality of life. Most patients strongly agreed or agreed with all Patient Satisfaction Questionnaire questions assessing confidence in tapinarof and satisfaction with efficacy (62.9%-85.8%), application ease and cosmetic elegance (79.9%-96.3%), and preference for tapinarof versus prior psoriasis therapies (55.3%-81.7%).Open-label; no control; may not be generalizable to all forms of psoriasis.Continued and durable improvements in health-related quality of life, high rates of patient satisfaction, and positive perceptions of tapinarof cream were demonstrated.
Plumbing mysterious RNAs in “dark genome” for the conquest of human diseases
Authors: Lisa A. Huang, Chunru Lin, Liuqing Yang
Journal: Molecular Therapy (2023)

Next-generation sequencing has revealed that less than 2% of transcribed genes are translated into proteins, with a large portion transcribed into noncoding RNAs (ncRNAs). Among these, long noncoding RNAs (lncRNAs) represent the largest group and are pervasively transcribed throughout the genome. Dysfunctions in lncRNAs have been found in various diseases, highlighting their potential as therapeutic, diagnostic, and prognostic targets. However, challenges, such as unknown molecular mechanisms and nonspecific immune responses, and issues of drug specificity and delivery present obstacles in translating lncRNAs into clinical applications. In this review, we summarize recent publications that have explored lncRNA functions in human diseases. We also discuss challenges and future directions for developing lncRNA treatments, aiming to bridge the gap between functional studies and clinical potential and inspire further exploration in the field.
JAMA Cardiology
Authors: Patrick O'gara, Marc Sabatine, Clyde Boston, Ann Yancy, Michael Pencina, Carolina North, Robert Harrington, Adrian Hernandez, Mhs Durham, North Carolina, Ajay Kirtane, New York, Roxana Mehran, Pradeep Natarajan, Kristen Boston, Seattle Patton, Washington Udelson, Sadiya Khan, Gregg Fonarow, Los Angeles, Sharlene Day, Laine Thomas, Akhil Narang, Julia Getts, Eugene Braunwald, Judith Hochman, Donald Lloyd-Jones, Scm Chicago, Michael Parmacek, Daniel Simon, Sidney Smith, Chapel Hill, Carolina Douglas, E Vaughan, Myron Weisfeldt, Maryland Douglas, P Zipes, Paul Armstrong, Shinya Goto, Peter Liu, Renato Lopes, Carolina Prabhakaran, Hugh Watkins, Harvey White, Habib Yacoub, Frs London, Gregory Curfman, Annette Flanagin, Michael Berkwits, Brenda Gregoline, Tracy Frey, Iris Lo, Kevin Brown, Bernadette Hromin, Erin Keenan, Rebecca Langley, Kris Simmons, Connie Manno, Sara Billings, Doug Brandt, Timothy Gray, Peter Olson, Juliet Orellana, Paul Ruich, Kirby Snell, Judith Ahlers, Stephanie Beckmeyer, Dawn Bielawski, Jane Calayag, Jan Clavey, Mary Coerver-Connolly, Amy Eutsey, Paul Jaworski, Laura King, Mary Kingzette, Martha Lentz, Jenny Mackay, Jennifer Maybin, Charon Pierson, Shilpa Shenvi, Thressa Smith, Divya Sreekumar, Donna Thordsen, Christine Tilles, Emma Underdown, Cara Wallace, Becki Weiss, Christina West, Caroline Woods, Erin Kato, Jacob Kendall-Taylor, Monica Mungle, Lenette Gardner-Gullens, Anna Bukowski, Lee Calibeo, Jordan Faber, Andrew Given, Tosca Hall, Emma Hyche, Kenneth Otani, Caroline Sietmann, Angelia Digital, Elena Guobyte, Daniel Morrow, Daniel Musisi, Shelly Steff, Jennifer Zeis, Eman Aly, Reuben Rios, Mary Ferkaluk, Sidra Bonner, Heather Hsu, Andrew Ibrahim, Karen Bucher, Andy Rekito, Nick Reback, Lohitha Kethu, Marla Erson, Joseph Thornton, Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Anna Frazier, Monica Smith, Julie Burton, Ronna Hewitt, Mary Sieck, Geneine Someren, Jamaal Vargas, Content Systems, Mike Bujewski, Nathan Mitre, Digital Production, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Dan Knowles, Joshua Lampinen, Natalie Marsh, Patricia Panek, Marla Seidell, La Son, Diggs Sledge, Julian Graphics, Joe Amft, Jonathan Chala, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Kelley Mcdonald, Joy Farrell, Maria Giannini, Sasha Grossman, Kate Lander, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Kirsten Bibbins-Domingo, Robert Bonow
Journal: JAMA Cardiology (2023)

science, and evidence-based health policy.Health equity, especially when supported by original science, is a leading editorial priority.
Potential Limitations for Assessing Adverse Posttraumatic Neuropsychiatric Sequelae With Wrist-Wearable Device and Self-report Survey—Reply
Authors: Laura D. Straus, Thomas C. Neylan, Samuel A. McLean
Journal: JAMA Psychiatry (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Reforming EU and national orphan drug regulations to improve outcomes for patients with rare diseases
Authors: Philip Kranz, Natalie McGauran, Rita Banzi, Can Ünal, Fabian Lotz, Thomas Kaiser
Journal: BMJ (2023)

<b>Philip Kranz and colleagues</b> argue that the alleged superior therapeutic benefit attributed to orphan drugs is often not supported by evidence from clinical trials and propose a reform of EU and national orphan drug regulations
Intravenous Immunoglobulin and Dermatomyositis-Associated Venous Thromboembolism
Authors: Elizabeth T. Rotrosen, Omid Zahedi Niaki, Bina Kassamali, Sarah Lonowski, Neda Shahriari, Avery LaChance, Ruth Ann Vleugels
Journal: JAMA Dermatology (2023)

This cohort study investigated the association between treatment of dermatomyositis with intravenous immunoglobulin and thromboembolic events.
Skeletal Muscle Mitochondrial Dysfunction and Exercise Intolerance in Heart Failure With Preserved Ejection Fraction
Authors: Ambarish Pandey, Neil Keshvani, Windy Alonso
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Potential Limitations for Assessing Adverse Posttraumatic Neuropsychiatric Sequelae With Wrist-Wearable Device and Self-report Survey
Authors: Ting-Chang Liao, Pei-Hsi Chou, Chia-Hao Hsu
Journal: JAMA Psychiatry (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Assessment of Cutaneous Vasculitis and Quality of Life
Authors: Sarah Mann, Aamir Hussain, Anisha B. Dua, Angelina Patrone, Kalen Larson, Peter A. Merkel, Robert G. Micheletti
Journal: JAMA Dermatology (2023)

This survey study assesses the health-related quality of life outcomes in adult patients with cutaneous manifestations of vasculitis.
Direct cleavage and activation of gasdermin B by allergens
Authors: Ronald Allan Panganiban, Chimwemwe Mwase, Jin‐Ah Park, Quan Lu
Journal: Allergy (2023)

Appendix S1 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Author Correction: Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut–lung axis
Authors: Mangalakumari Jeyanathan, Maryam Vaseghi-Shanjani, Sam Afkhami, Jensine A Grondin, Alisha Kang, Michael R D'Agostino, Yushi Yao, Shreya Jain, Anna Zganiacz, Zachary Kroezen, Meera Shanmuganathan, Ramandeep Singh, Anna Dvorkin-Gheva, Philip Britz-McKibbin, Waliul I Khan, Zhou Xing
Journal: Nature Immunology (2023)
Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Lina Scandalis, Dalane W. Kitzman, Barbara J. Nicklas, Mary Lyles, Peter Brubaker, M. Benjamin Nelson, Michelle Gordon, John Stone, Jaclyn Bergstrom, P. Darrell Neufer, Erich Gnaiger, Anthony J. A. Molina
Journal: JAMA Cardiology (2023)

The pathophysiology of exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF) remains incompletely understood. Multiple lines of evidence suggest that abnormal skeletal muscle metabolism is a key contributor, but the mechanisms underlying metabolic dysfunction remain unresolved.
Laundry detergents and surfactants‐induced eosinophilic airway inflammation by increasing <scp>IL</scp>‐33 expression and activating <scp>ILC2s</scp>
Authors: Kyoko Saito, Keisuke Orimo, Terufumi Kubo, Masato Tamari, Ayako Yamada, Kenichiro Motomura, Hiroki Sugiyama, Ryo Matsuoka, Naoko Nagano, Yuka Hayashi, Ken Arae, Mariko Hara, Masashi Ikutani, Tatsuki Fukuie, Katsuko Sudo, Akio Matsuda, Yukihiro Ohya, Shigeharu Fujieda, Hirohisa Saito, Susumu Nakae, Kenji Matsumoto, Cezmi A. Akdis, Hideaki Morita
Journal: Allergy (2023)

Epidemiological studies demonstrated that cleaning work and frequent use of cleaning products are risk factors for asthma. Laundry detergents have been reported to have epithelial barrier-opening effects. However, whether laundry detergents directly induce airway inflammation and its mechanisms in vivo remain to be elucidated.Two commercial laundry detergents and two commonly used surfactants for cleaning and cosmetics (sodium lauryl sulfate and sodium dodecyl benzene sulfonate) were intranasally administered to mice. Lungs were analyzed using flow cytometry, histology, ELISA, and quantitative PCR. Human bronchial epithelial cells were stimulated with laundry detergents and analyzed using quantitative PCR and western blotting. Involvement of oxidative stress was assessed using an antioxidant. Dust samples from homes were analyzed to determine their detergent content by measuring their critical micelle concentration (CMC).The administered laundry detergents and surfactants-induced eosinophilic airway inflammation accompanied by increased IL-33 expression and activation of group 2 innate lymphoid cells (ILC2s). Detergent-induced eosinophilic airway inflammation was significantly attenuated in Rag2-/- Il2rg-/- , Il33-/- mice, and also in wild-type mice treated with NAC. Detergent-induced IL-33 expression in airways was attenuated by NAC treatment, both in vivo and in vitro. CMCs were found in all of the tested dust extracts, and they differed significantly among the homes.The laundry detergents and surfactants-induced eosinophilic airway inflammation in vivo through epithelial cell and ILC2 activation. They induced IL-33 expression in airway epithelial cells through oxidative stress. Furthermore, detergent residues were present in house dust and are presumably inhaled into the airway in daily life.
Subgingival instrumentation
Authors: Cristiano Tomasi, Kajsa H. Abrahamsson, Danae Apatzidou
Journal: Periodontology 2000 (2023)

The S3-level clinical guidelines for the treatment of patients with periodontitis stages I-III published by the European Federation of Periodontology in 2020, suggest a pre-established stepwise approach for oral-healthcare professionals with precise therapeutic pathways. The second step of this approach consists of the subgingival instrumentation of periodontal pockets by non-surgical means to disrupt the microbial biofilm and remove soft and mineralized deposits This step aims to resolve periodontal inflammation by closure of periodontal pockets (probing pocket depth ≤ 4 mm, absence of bleeding on probing) employing different types of instruments and treatment protocols toward this end. Novel non-surgical treatment approaches that adopt micro instruments or subgingival application of biological agents have been recently tested. Subgingival instrumentation has been shown to effectively restore the subgingival microbiota to one associated with periodontal health and to modulate the inflammatory response. The outcomes of the subgingival instrumentation have to be evaluated in order to guide the therapist in providing additional but focused treatment in the remaining pockets OR at sites with residual inflammation. Of great importance is the impact that non-surgical periodontal treatment has on the patient's well-being, based on evidence that emerges from studies evaluating patient related outcomes and quality of life.
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Authors: Haijun Cui, Xueyuan Sun, Marcel Schilling, Christel Herold‐Mende, Markus Reischl, Pavel A. Levkin, Anna A. Popova, Şevin Turcan
Journal: Advanced Healthcare Materials (2023)

Abstract To address the challenge of drug resistance and limited treatment options for recurrent gliomas with IDH1 mutations, a highly miniaturized screening of 2208 FDA‐approved drugs is conducted using a high‐throughput droplet microarray (DMA) platform. Two patient‐derived temozolomide‐resistant tumorspheres harboring endogenous IDH1 mutations (IDH1 mut ) are utilized. Screening identifies over 20 drugs, including verteporfin (VP), that significantly affected tumorsphere formation and viability. Proteomics analysis reveals that nuclear pore complex may be a potential VP target, suggesting a new mechanism of action independent of its known effects on YAP1. Knockdown experiments exclude YAP1 as a drug target in tumorspheres. Pathway analysis shows that NUP107 is a potential upstream regulator associated with VP response. Analysis of publicly available genomic datasets shows a significant correlation between high NUP107 expression and decreased survival in IDH1 mut astrocytoma, suggesting NUP107 may be a potential biomarker for VP response. This study demonstrates a miniaturized approach for cost‐effective drug repurposing using 3D glioma models and identifies nuclear pore complex as a potential target for drug development. The findings provide preclinical evidence to support in vivo and clinical studies of VP and other identified compounds to treat IDH1 mut gliomas, which may ultimately improve clinical outcomes for patients with this challenging disease.
Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
Authors: Melanie Langhammer, Julia Schöpf, Timo Jaquet, Katharina Horn, Moritz Angel, Corinna Spohr, Daniel Christen, Franziska Maria Uhl, Tiago Maié, Henrike Jacobi, Thorsten B. Feyerabend, Julia Huber, Marcus Panning, Cassian Sitaru, Ivan Costa, Robert Zeiser, Konrad Aumann, Heiko Becker, Till Braunschweig, Steffen Koschmieder, Khalid Shoumariyeh, Michael Huber, Mirle Schemionek-Reinders, Tilman Brummer, Sebastian Halbach
Journal: Leukemia (2023)

Abstract The persistence of leukemic stem cells (LSCs) represents a problem in the therapy of chronic myeloid leukemia (CML). Hence, it is of utmost importance to explore the underlying mechanisms to develop new therapeutic approaches to cure CML. Using the genetically engineered ScltTA/TRE-BCR::ABL1 mouse model for chronic phase CML, we previously demonstrated that the loss of the docking protein GAB2 counteracts the infiltration of mast cells (MCs) in the bone marrow (BM) of BCR::ABL1 positive mice. Here, we show for the first time that BCR::ABL1 drives the cytokine independent expansion of BM derived MCs and sensitizes them for FcεRI triggered degranulation. Importantly, we demonstrate that genetic mast cell deficiency conferred by the Cpa3 Cre allele prevents BCR::ABL1 induced splenomegaly and impairs the production of pro-inflammatory cytokines. Furthermore, we show in CML patients that splenomegaly is associated with high BM MC counts and that upregulation of pro-inflammatory cytokines in patient serum samples correlates with tryptase levels. Finally, MC-associated transcripts were elevated in human CML BM samples. Thus, our study identifies MCs as essential contributors to disease progression and suggests considering them as an additional target in CML therapy.
Fibroid Prevalence—Still So Much to Learn
Authors: Quaker E. Harmon, Ky’Era V. Actkins, Donna D. Baird
Journal: JAMA Network Open (2023)

The report from Huang et al 1 elsewhere in JAMA Network Open used a community-based cohort with systematic ultrasonographic screening to document the high fibroid prevalence in reproductiveaged participants (20%), the 2-to 3-fold higher prevalence of fibroids in Black or Asian-Chinese individuals compared with White or Hispanic individuals, and the early age of fibroid onset in both Black and Asian-Chinese participants.In the context of fibroid research, estimates of fibroid prevalence in a diverse community sample are limited.Fibroid-focused epidemiologic research is rare, yet the scarcity of data cannot be explained by unique difficulties of studying this condition given that fibroids are not hard to diagnose.Most studies rely on suboptimal study designs, including secondary analysis of studies designed for other outcomes.The study by Huang et al 1 used ultrasonographic imaging for diagnosis, but the data were collected for a different hypothesis, which may lead to bias.The eligibility criteria for the primary study excluded those using hormonal contraception and those with a history of pelvic surgery.This may underestimate fibroid prevalence
Diffuse large B‐cell lymphoma at risk of secondary <scp>CNS</scp> involvement: The inefficacy of intravenous high‐dose methotrexate <scp>CNS</scp> prophylaxis and the importance of baseline cerebrospinal fluid analysis
Authors: Rory Bennett, Anna Ruskova, Christin Coomarasamy, Edward Theakston, Leanne Berkahn, Sharon Jackson, Mina Christophers, Stephen Wong, Samar Issa
Journal: American Journal of Hematology (2023)

High-dose intravenous methotrexate (HD-MTX) CNS prophylaxis in high-risk diffuse large B cell lymphoma (DLBCL) remains controversial. We describe real-world CNS relapse incidence following baseline cerebrospinal fluid (CSF) analysis to exclude asymptomatic leptomeningeal involvement in newly diagnosed high-risk DLBCL patients with versus without single-route HD-MTX CNS prophylaxis. Consecutively diagnosed high-risk systemic DLBCL patients without leptomeningeal involvement by CSF analysis (noCNS) were identified retrospectively. Five-year CNS relapse incidence and survival outcomes were examined, as stratified by receipt of HD-MTX prophylaxis. Secondary analysis of survival outcomes in patients with synchronous leptomeningeal involvement (CNSinv) by CSF analysis at diagnosis were compared with the noCNS group. No significant difference in 5-year CNS relapse incidence was observed following HD-MTX prophylaxis versus no prophylaxis (total n = 445) despite similar CNS-IPI risk; 6.2% versus 5.6%, adjusted HR 1.08 (95% CI 0.41-2.85), p = .88; nor in 5-year progression free survival (PFS) or overall survival (OS) risk. Of CNSinv patients, 93.3% had ≥1 extranodal site. Increased CNS relapse/progression risk (5-year risk; HR 10.7 [95% CI 5.35-21.37], p < .0001) and inferior PFS and OS were observed in CNSinv versus all noCNS patients. The CNSinv group had superior OS compared with noCNS patients who later experienced CNS relapse (HR 0.55, p = .052). HD-MTX prophylaxis does not reduce CNS relapse risk in high-risk systemic DLBCL without leptomeningeal involvement by CSF analysis at diagnosis. Asymptomatic patients with synchronous leptomeningeal involvement on baseline CSF examination are at increased risk of further CNS disease events and inferior survival compared to patients without CSF involvement.